CDK4 and neoplasm: Our finding of RB1 deletions in 34% of tumours with CDKN2A deletion makes responses to CDK4/CDK6 antagonists less likely and underpins our finding that the CDK4/CDK6 inhibitor Palbociclib had marginal effects on primary cell survival.